BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fromer MW, Scoggins CR, Egger ME, Philips P, McMasters KM, Martin Ii RCG. Preventing Futile Liver Resection: A Risk-Based Approach to Surgical Selection in Major Hepatectomy for Colorectal Cancer. Ann Surg Oncol 2021. [PMID: 34522997 DOI: 10.1245/s10434-021-10761-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Wong GYM, Diakos C, Molloy MP, Hugh TJ. Current Challenges in Defining Futile Liver Resection and Predicting Early Recurrence After Curative-Intent Treatment for Colorectal Liver Metastases. Ann Surg Oncol 2022. [DOI: 10.1245/s10434-022-12828-y] [Reference Citation Analysis]
2 Kazi M, Desouza A, Saklani A. What are the preoperative predictors of a futile pelvic exenteration in rectal cancers? European Journal of Surgical Oncology 2022. [DOI: 10.1016/j.ejso.2022.10.022] [Reference Citation Analysis]
3 Musick JR, Philips P, Scoggins CR, Egger ME, Mcmasters KM, Martin RC. Laparoscopic microwave ablation versus percutaneous microwave ablation of hepatic malignancies: Efficacy and recurrence-free survival outcomes in patients. Surgery 2022. [DOI: 10.1016/j.surg.2022.06.054] [Reference Citation Analysis]
4 Fromer MW, Scoggins CR, Egger ME, Philips P, McMasters KM, Martin RCG 2nd. Authors' Reply to Preventing Futile Liver Resection: Biology Should be Central in Patients' Selection. Ann Surg Oncol 2022. [PMID: 35699813 DOI: 10.1245/s10434-022-11955-w] [Reference Citation Analysis]
5 Ribero D, Aprile G. Preventing Futile Liver Resection: Biology Should be Central in Patients' Selection. Ann Surg Oncol 2022. [PMID: 35622182 DOI: 10.1245/s10434-022-11952-z] [Reference Citation Analysis]
6 Germani MM, Borelli B, Boraschi P, Antoniotti C, Ugolini C, Urbani L, Morelli L, Fontanini G, Masi G, Cremolini C, Moretto R. The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features. Cancer Treat Rev 2022;106:102382. [PMID: 35334281 DOI: 10.1016/j.ctrv.2022.102382] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]